Clinical Trials Logo

Clinical Trial Summary

Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.


Clinical Trial Description

Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored ideally at -20C and thaw once for use, then will be kept in the refrigerator at +4C, to be taken in multiple doses. ;


Study Design


Related Conditions & MeSH terms

  • Persistent Corneal Epithelial Defect

NCT number NCT02979912
Study type Interventional
Source University of Jordan
Contact
Status Completed
Phase Phase 1/Phase 2
Start date February 16, 2017
Completion date January 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT00988494 - Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect Phase 2
Completed NCT03687632 - ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects Phase 2
Recruiting NCT05966493 - A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED Phase 2/Phase 3
Completed NCT05436288 - A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects Phase 2
Recruiting NCT05727878 - Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED Phase 2
Terminated NCT05066698 - ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects Phase 2
Withdrawn NCT05172349 - Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers Phase 2